Search
for
Sort by
Research 61–90 of 1000+
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- 378 Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review
- Janus kinase inhibitor as a therapeutic option in alopecia areata. Case report
- Komplet remission ved behandling med JAK-hæmmer hos en patient med alopeciatotalis
- Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib—A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- A review of Janus kinase inhibitor use in scarring alopecia
- Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
- Inhibiting Janus kinases to treat alopecia areata
- Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
- BH20 An unintended sequela of hair regrowth: severe Janus kinase inhibitor-associated acneiform eruption in alopecia areata
- BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
- Use of intramuscular triamcinolone acetonide in intermediate responders to janus kinase inhibition for alopecia areata: Case report
- 151 Efficacy and adverse effects of oral Janus kinase inhibitor (JAKi) use in patients with lichen planopilaris: a retrospective case series and systematic review
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- Tofacitinib for the treatment of lichen planopilaris: A case series
- The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1
- Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
- High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata